Proprietary algorithm positions IzoView to redefine global standards and expectations for image quality and safety in breast CT Trained on 15 years of specialized breast CT data and protected as a trade secret, giving Izotropic a durable competitive edge AI enhances IzoView’s image quality by reducing CT image noise without increasing radiation dose VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 28, 2025 (GLOBE... Read More

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - August 26, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (" Izotropic ", or the " Company "), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it intends to complete a small non-brokered... Read More

VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO ) (OTCQB: IZOZF ) (FSE: 1R3 ) (“ Izotropic ”, or the “ Company ”) , a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of BreastCT.com , a new online... Read More

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - August 12, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (" Izotropic ", or the " Company "), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of its new corporate website and... Read More

VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO ) (OTCQB: IZOZF ) (FSE: 1R3 ) (“ Izotropic ”, or the “ Company ”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of its new podcast series. The... Read More

Global breast imaging market projected to reach $8.69 billion by 2030, with IzoView addressing key clinical and commercial trends driving demand Company positioned to lead in dense breast imaging, where rising incidence and new screening mandates are expanding access to advanced technologies IzoView optimized for AI-readiness, addressing a critical need as imaging centers adopt smart workflows and algorithmic support tools... Read More

Strategic awareness initiatives underway ahead of IzoView commercialization Company podcast and breasct.com website in development to expand engagement Market-facing activities aligned with investor communications and corporate milestones Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - July 15, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (" Izotropic " or the " Company "), a... Read More

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - June 13, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (" Izotropic " or the " Company "), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into an agreement with... Read More

License agreement enables U.S. FDA approval or foreign equivalent (CE mark) Amendment aligns with Company's timelines for IzoView product launch Agreement amendment fees of USD $85K payable in installments Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - June 10, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (" Izotropic " or the " Company "), a medical device company... Read More

Regulatory alignment with FDA confirmed, clearing path to pivotal U.S. clinical trial 150-page strategic business plan and advanced financial models completed Investor outreach launched to fund clinical execution and market entry Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - May 16, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (" Izotropic " or the " Company "), a medical... Read More

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - April 2, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (" Izotropic " or the " Company "), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has engaged an International... Read More

FDA meeting facilitated positive collaborative exchange Key topics included the clinical study protocol synopsis, the benefits versus risks of contrast-enhancement, and the management of breast cancers found on IzoView Breast CT that are not visible on digital breast tomosynthesis Izotropic to submit meeting minutes to the FDA prior to more detailed disclosure Vancouver, British Columbia and Sacramento, California--(Newsfile... Read More

CEO to discuss IzoView's competitive advantage, expansion strategy, and potential revenue models Event includes live Q and A, attendance is complimentary Individual and institutional investors, advisors, and analysts welcome Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - March 10, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (" Izotropic " or the " Company "), a medical device... Read More

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 19, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (" Izotropic " or the " Company "), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that the U.S. Food and Drug... Read More

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 14, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (" Izotropic " or the " Company "), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that further to its February 7 th... Read More

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 7, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (" Izotropic " or the " Company "), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announced today that it intends to complete a small... Read More

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 5, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (" Izotropic " or the " Company "), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces it is rescheduling its attendance and... Read More

CEO to present overview of Company value proposition, unique catalysts, and near-term objectives Event includes live Q and A, attendance is complimentary Individual and institutional investors, advisors, and analysts welcome Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 3, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (" Izotropic " or the " Company "), a medical... Read More

Unique dense breast tissue focus to drive expedited recruitment rates; modular clinical study design reduces time to PMA submission by ~6 months 3 Site U.S.-based clinical study enables early data collection to kickstart European CE Mark Application Company to announce development of 2 new medical imaging devices in the next... Read More

Company listed in Research and Markets' announcement and description of new research report on the U.S. Breast Cancer Screening and Diagnostic Market "U.S. breast cancer screening and diagnostic [device] market was valued at $1.55 billion in 2024 and is anticipated to reach $2.34 billion by the end of 2030, at a CAGR of 7.05% during the forecast period 2024-2030 1 " Report supports Company's regulatory strategy for IzoView... Read More

New FDA Consultant is the former Director of the Division of Imaging, Diagnostics, and Software Reliability at the U.S Food and Drug Administration New Biostatistical Consultant is the former Deputy Director of the Biostatistics and Data Management Center of the American College of Radiology Imaging Network, an NIH-funded cooperative that conducts clinical trials to evaluate the use of diagnostic imaging and image-guided... Read More

A screening indication for women with dense breast tissue adjunctive to 3D mammography increases the market size for annual IzoView scans by over 800% 1 for initial approval and product launch Regulatory strategy responds to the "urgent call 2 " from the U.S. Preventative Services Task Force for solutions to finding breast cancers earlier in women with dense breast tissue Comprehensive filing includes patient acquisition and... Read More

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2024) - Izotropic Corporation ( CSE: IZO ) ( OTCQB: IZOZF ) ( FSE: 1R3 ) (" Izotropic " or the " Company "), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, announces that due to the suspension of mail service in Canada due to the nationwide strike of the Canadian Union of Postal Workers, that the notice of meeting,... Read More

Vancouver, British Columbia--(Newsfile Corp. - August 23, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (" Izotropic " or the " Company "), a medical device company commercializing IzoView, a breast CT (computed tomography) imaging system, is pleased to announce that it is pursuing a regulatory strategy in the U.S. and EU to launch IzoView as a diagnostic device indicated for use in patients with dense... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Izotropic Corporation ( CSE: IZO ) ( OTCQB: IZOZF ) ( FSE: 1R3 ) (" Izotropic " or the " Company ") - Further to the Company's news release of June 6, 2024, the Company is pleased to announce that it has completed the first tranche of its non-brokered private placement financing (the " Offering "), whereby the Company issued 1,800,000 units (each, a " Unit ") at... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (" Izotropic " or the " Company "), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, announced today that it intends to complete a small non-brokered private placement financing (the " Offering ") of up to 3,000,000 units of the Company, (each a " Unit ") at a... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (" Izotropic " or the " Company "), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, that produces images of anatomy for non-invasive characterization of tissue with an application in breast imaging, announces that further to its January 8 th disclosure , it... Read More

VANCOUVER, BC – TheNewswire - January 8, 2024 – Izotropic Corporation (“ Izotropic ” or the “ Company ”) (CSE: IZO ) (OTC: IZOZF ) (FSE: 1R3 ), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, that produces images of anatomy for non-invasive characterization of tissue with an application in breast imaging, provides an update on its regulatory status with the U.S. Food and Drug... Read More

VANCOUVER, BC – TheNewswire - December 22, 2023 – Izotropic Corporation (“ Izotropic ” or the“ Company ”) (CSE: IZO ) (OTC: IZOZF ) (FSE: 1R3 ), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, that produces images of anatomy for non-invasive tissue characterization with an application in breast imaging, announces the results of its Annual General Meeting and Special Meeting held... Read More

Vancouver, British Columbia--(Newsfile Corp. - November 1, 2023) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (" Izotropic " or the " Company "), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, that produces images of anatomy for non-invasive tissue characterization with an application in breast imaging, announced today that it completed its previously announced... Read More

Vancouver, BC - TheNewswire - September 27, 2023 - Izotropic Corporation (“ Izotropic ” or the “ Company ”) (CSE: IZO ) (OTC: IZOZF ) (FSE: 1R3 ), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, that produces images of anatomy for non-invasive tissue characterization with the first application in breast imaging, announced today it has confirmed a pre-submission meeting date with... Read More

Vancouver, BC - TheNewswire - September 20, 2023 - Izotropic Corporation (“ Izotropic ” or the “ Company ”) (CSE: IZO ) (OTCQ: IZOZF ) (FSE: 1R3 ), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, that produces images of anatomy for non-invasive tissue characterization with the first application in breast imaging, announced today that, further to its news release on September 13,... Read More

Vancouver, BC - TheNewswire - September 13, 2023 - Izotropic Corporation (“ Izotropic ” or the “ Company ”) (CSE: IZO ) (OTC: IZOZF ) (FSE: 1R3 ), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, that produces images of anatomy for non-invasive tissue characterization with the first application in breast imaging, announced today that it intends to complete a non-brokered private... Read More

Vancouver, British Columbia--(Newsfile Corp. - September 6, 2023) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (" Izotropic " or the " Company "), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, that produces images of anatomy for non-invasive tissue characterization with the first application in breast imaging, announced today that it has completed a... Read More

VANCOUVER, BC – TheNewswire - JUNE 27, 2023 – Izotropic Corporation (“ Izotropic ” or the “ Company ”) (CSE: IZO ) (OTC: IZOZF ) (FSE: 1R3 ), a medical device company commercializing IzoView, a 360-degree computed tomography (CT) imaging system designed for breast imaging announced that it has engaged Douglas McKay and Associates (“ DMA ”) to assist the Company with its communications and financing initiatives. Subject to... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 20, 2023) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a 360-degree computed tomography (CT) imaging system designed for breast imaging and cancer diagnosis, announced that it is modifying its U.S. FDA market approval pathway and strategy by deferring its plan to undertake a... Read More

V ANCOUVER, BC – TheNewswire - JUNE 8, 2023 – Izotropic Corporation (“ Izotropic ” or the “ Company ”) (CSE: IZO ) (OTC: IZOZF ) (FSE: 1R3 ), a medical imaging device company, announces that effective May 31, 2023, Dr. John McGraw has resigned as Chief Executive Officer (CEO) for personal reasons and has stepped down from the Company’s Board of Directors. Dr. McGraw will remain an Advisor to the Company and consult on future... Read More

VANCOUVER, BC – TheNewswire - May 15, 2023 – Izotropic Corporation (“ Izotropic ” or the “ Company ”) (CSE: IZO ) (OTC: IZOZF ) (FSE: 1R3 ), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers, announces the Company conducted a pre-submission meeting with the FDA on April 28, 2023 to present a detailed... Read More

VANCOUVER, BC – TheNewswire - April 27, 2023 – Izotropic Corporation (“ Izotropic ” or the “ Company ”) (CSE: IZO ) (OTC: IZOZF ) (FSE: 1R3 ), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers, announced that in addition to pursuing the development of the device, it has been exploring an enhanced... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 23, 2023) - Izotropic Corporation (CSE: IZO ) (OTCQB: IZOZF ) (FSE: 1R3 ) (" Izotropic " or the " Company "), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers, releases statements from select key members of its technical and scientific teams... Read More

Vancouver, BC - TheNewswire - January 12, 2023 - Izotropic Corporation (“ Izotropic ” or the “ Company ”) (CSE:IZO) (OTC:IZOZF) (FSE:1R3), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers, announces that it has created a compensation committee (the “Compensation Committee” or the “Committee”) to... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 9, 2023) - Izotropic Corporation (CSE: IZO ) (OTCQB: IZOZF ) (FSE: 1R3 ) (" Izotropic " or the " Company "), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers, is pleased to release the first video showcasing the completed engineering of IzoView.... Read More

VANCOUVER, BC – TheNewswire - January 9, 2023 – Izotropic Corporation (“ Izotropic ” or the “ Company ”) (CSE: IZO ) (OTC: IZOZF ) (FSE: 1R3 ), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers, is pleased to release the first video showcasing the completed engineering of IzoView. This video is the... Read More

VANCOUVER, BC – TheNewswire - January 4, 2023 – Izotropic Corporation (“ Izotropic ” or the “ Company ”) (CSE: IZO ) (OTC: IZOZF ) (FSE: 1R3 ), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers, reports the results of the board meeting held December 29, 2022. The Board of Directors is pleased to... Read More

VANCOUVER, BC – TheNewswire - December 28, 2022 – Izotropic Corporation (“ Izotropic ” or the “ Company ”) (CSE: IZO ) (OTC: IZOZF ) (FSE: 1R3 ), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers, informs shareholders that news announcements originally scheduled to be released before the yearend have... Read More

VANCOUVER, BC – TheNewswire - December 20, 2022 – Izotropic Corporation (“ Izotropic ” or the “ Company ”) (CSE: IZO ) (OTC: IZOZF ) (FSE: 1R3 ), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers, announces the results of its Annual General Meeting held on December 19, 2022. Company matters submitted... Read More

VANCOUVER, BC – TheNewswire – December 1 , 2022 – Izotropic Corporation (“ Izotropic ” or the “ Company ”) (CSE: IZO ) (OTC: IZOZF ) (FSE: 1R3 ), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers is pleased to announce that it has completed the final engineering of IzoView. IzoView is now fully... Read More